Adenoid Cystic Carcinoma of the Breast: An Oncological Center’s Experience

Ana Margarida Correia\textsuperscript{a,\textsection,\ast}, Rafael Fernandes\textsuperscript{b,\section}, Teresa Dias\textsuperscript{a}, Madalena Souto Moura\textsuperscript{c}, Rita Canotilho\textsuperscript{a}, Catarina Baia\textsuperscript{a}, Paula Pinto\textsuperscript{a}, Joaquim Abreu de Sousa\textsuperscript{a}

\textsuperscript{a}Surgical Oncology Department, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal
\textsuperscript{b}General Surgery Department, Hospital de Santa Cruz, Centro Hospitalar de Lisboa Ocidental, Portugal
\textsuperscript{c}Anatomical Pathology Department, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal
\textsuperscript{\section}These authors contributed equally to this work

ARTICLE INFO

Received: 22 August 2021
Revised: 24 September 2021
Accepted: 03 October 2021

ABSTRACT

Background: Adenoid cystic carcinoma of the breast (ACCB) is a rare breast malignancy. Despite often being a triple negative tumor, it has a favorable prognosis, with low rates of recurrence and progression. The ideal treatment of ACCB is debatable; thus, the aim of this study was to characterize a population diagnosed with ACCB and to evaluate the treatment outcomes.

Methods: We performed a single-center retrospective analysis of patients with a histological diagnosis of ACCB treated at our dedicated Oncological Center between 1987 and 2020. The patients were identified in collaboration with the Anatomical Pathology Department, which also reviewed the surgical pathology reports.

Results: Thirteen women with a median age of 68 years old were diagnosed with ACCB. The most frequent clinical diagnosis was a breast nodule (n=5); the preoperative image was suggestive of malignancy in nine patients, with seven being diagnosed with a ACCB in the preoperative biopsy. Regarding treatment, nine patients underwent conservative surgery, but three required re-excision. Sentinel lymph node biopsy (SLNB) was performed in seven patients, none revealing metastases; one patient had stage III ACCB and was initially treated with a modified radical mastectomy (MRM); the remaining were stage I (n=7) and II (n=5). Adjuvant radiotherapy was performed in eight patients, and two were initially proposed for chemotherapy but were considered unfit. With a median follow-up of 123 months (16-407), one case of local recurrence and two cases of distant metastasis were identified, one of whom died of disease.

Conclusion: ACCB is a rare tumor with a good prognosis; however, as demonstrated, it can present an aggressive behavior. Conservative surgery and adjuvant radiotherapy are the indicated treatment and SLNB may be omitted in grade 1 tumors.

INTRODUCTION

Adenoid cystic carcinoma of the breast (ACCB) was first described by Geschickter and Copeland in 1945 and constitutes a rare type of primary breast cancer, accounting for 0.1% of all primary breast malignancies. ACCB is a slow-growing tumor that occurs more frequently in postmenopausal women.
aged between 50 and 60 years. Bilateral synchronous carcinoma is rare and the most frequent clinical presentation is a well-defined retroareolar mass or mastalgia, with a small percentage of cases being incidentally detected in screening exams of asymptomatic women. A surgical or percutaneous biopsy is necessary to obtain the diagnosis, as there are no pathognomonic imaging signs that can point to this entity. Histologically this tumor is similar to the adenoid cystic carcinoma of the salivary glands and is composed of a dual-cell population of epithelial and myoepithelial-basal cells. Despite having a triple negative phenotype, which is absence of expression of estrogen receptors (ER), progesterone receptors (PR) and HER2 in the immunohistochemical analysis, ACCB constitutes a separate subgroup with a very favorable prognosis, local recurrence rate of 3–18%, low rates of progression, as well as a low mortality rate (7.1%). This triple negative phenotype may also help to distinguish cribriform areas of ACCB from invasive cribriform carcinomas which exhibit some morphological similarities but are generally strongly and diffusely immunoreactive for ER and PR. Furthermore, invasive cribriform carcinomas are not composed of a dual cell population (epithelial and myoepithelial), expressing only epithelial markers.

The mainstay of treatment of ACCB has not yet been established due to its rare incidence and indolent behavior, which can be confirmed in the literature, as there are mainly case reports, or small series. Regarding histological classification, several scores can be applied. Ro et al. suggested a division into 3 prognostic groups, according to architectural and cytological features, namely the proportion of solid and cystic components: grade 1 if there is a predominance of glands and cystic components and absence of solid ones; grade 2 when there are less than 30% of solid components; and grade 3 if there are more than 30% of solid components. According to the authors, the higher the proportion of solid components, the more aggressive the tumor and greater the risk of recurrence and metastases. Additionally, the histologic grade assessed by the Nottingham Score may also be used, with prognostic value, which takes into consideration three factors: tubule formation, nuclear pleomorphism and mitotic activity. Recently, the 2019 World Health Organization classification of breast tumors suggested a division of ACCB into three different histologic subtypes, also with prognostic significance: classic (described as a low-grade neoplasia), solid-basaloid and ACCB with high-grade transformation (both with high grade areas). Most studies suggest an advantage in associating radiotherapy to wide local excision, whereas chemotherapy appears to have no benefit and is not recommended, according to ESMO. Typically, ACCB is a low-grade tumor and has a small percentage of nodal involvement at diagnosis (about 5%). Distant metastatic disease at diagnosis is extremely rare. When metastases are present, the lung is the most common location, although bone, liver, brain and kidney can also be affected. In such cases, usually there is no axillary involvement. Given the low rate of lymphatic spread and lymph node involvement, the role of sentinel lymph node biopsy (SLNB) is still a matter of debate, with a study revealing a similar 10-year relative cumulative survival in patients with unknown nodal status when compared to node negative ones. The same authors also acknowledged the absence of nodal metastases in tumors smaller than 1.4 cm in a series of 244 patients and another study of 338 patients reported only two cases of nodal metastases in tumors smaller than 2 cm.

Our goal was to characterize the population of patients diagnosed with ACCB in our institution, analyze the histopathological features, observe the instituted treatment and evaluate the oncological outcome. In this paper, we intend to help clarifying the best management of this rare breast malignancy.

**METHODS**

This is a single-center retrospective analysis of patients with a histological diagnosis of ACCB, treated at IPO-Porto from January 1987 to December 2020. The patients were identified in collaboration with the Anatomical Pathology Department, which also reviewed the surgical pathology reports. This Department used the Nottingham Score for tumor grading, since the 2019 World Health Organization Classification of Breast Tumors had not yet been published. Data on demographics, clinical presentation, treatment and outcome was collected by consulting the patients’ medical files.

**RESULTS**

We obtained a sample of 13 female patients, with a median age of 68 years (43–82) with only one of them being premenopausal (Table 1). None of the patients had a known family history of breast malignancy, and two of them had a prior diagnosis of fibroadenoma.

Five cases presented with a breast nodule (38.5%), four as an abnormal imaging finding in screening exams (30.8%), three complained of mastalgia (23.1%) and one of nipple discharge. There was no difference in the laterality of the tumors, with the upper quadrants being the most frequent location (n = 9) (4 in UOQ, 2 in UQT, 3 in UIT, 1 retroareolar, 2 in OQT and 1 in LOQ). The preoperative imaging findings were suggestive of malignancy in nine patients; none of the 13 patients had a multifocal/multicentric tumor and the median lesion size was 2 cm on ultrasound (0.9 – 8 cm). A preoperative
biopsy was available in 12 patients, namely eight cases of core needle biopsy (61.5%) and four cases of fine needle aspiration, with the latter performed in the early years (Table 2). A diagnosis of Adenoid Cystic Carcinoma was obtained in seven of these biopsies and information regarding tumor grade and immunohistochemistry was missing in four of them. The remaining were hormone receptor (HR) negative in one case and triple negative in two cases; three tumors were grade 1.

**Table 1: Population characteristics.**

| Patient | Age (years) | Hormonal status | Prior breast lesions | Clinical presentation | Laterality |
|---------|-------------|-----------------|----------------------|-----------------------|------------|
| 1       | 54          | Postmenopausal  | Yes, Fibroadenoma    | Palpable nodule       | Left       |
| 2       | 81          | Postmenopausal  | No                   | Palpable nodule       | Left       |
| 3       | 74          | Postmenopausal  | No                   | Palpable nodule       | Right      |
| 4       | 75          | Postmenopausal  | No                   | Palpable nodule       | Right      |
| 5       | 43          | Premenopausal   | No                   | Mastalgia             | Right      |
| 6       | 68          | Postmenopausal  | No                   | Asymptomatic          | Right      |
| 7       | 73          | Postmenopausal  | No                   | Nipple discharge      | Right      |
| 8       | 74          | Postmenopausal  | No                   | Mastalgia             | Right      |
| 9       | 72          | Postmenopausal  | Yes, Fibroadenoma    | Asymptomatic          | Left       |
| 10      | 51          | Postmenopausal  | No                   | Asymptomatic          | Left       |
| 11      | 61          | Postmenopausal  | No                   | Mastalgia             | Right      |
| 12      | 55          | Postmenopausal  | No                   | Asymptomatic          | Left       |
| 13      | 54          | Postmenopausal  | No                   | Palpable nodule       | Left       |

**Table 2: Characterization of the preoperative biopsy.**

| Patient | Preoperative Biopsy - Pathology report | Grade | Immunohistochemistry | Institution | Year of diagnosis |
|---------|---------------------------------------|-------|----------------------|-------------|-------------------|
| 1       | FNA - No signs of malignancy          | NA    | NA                   | IPO-Porto   | 1987              |
| 2       | FNA - Suspected of malignancy         | NA    | NA                   | IPO-Porto   | 1999              |
| 3       | FNA - Adenoid cystic carcinoma        | NA    | NA                   | IPO-Porto   | 2000              |
| 4       | CNB - Complex proliferative lesion    | NA    | NA                   | IPO-Porto   | 2003              |
| 5       | NA                                    | NA    | NA                   | External    | 2003              |
| 6       | FNA - Adenoid cystic carcinoma        | NA    | NA                   | External    | 2004              |
| 7       | CNB - DCIS + focal invasive carcinoma | NA    | NA                   | IPO-Porto   | 2009              |
| 8       | CNB - Adenoid cystic carcinoma        | 1     | Negative HR          | IPO-Porto   | 2011              |
| 9       | CNB - Adenoid cystic carcinoma        | NA    | NA                   | External    | 2016              |
| 10      | CNB - Adenoid cystic carcinoma        | 1     | NA                   | External    | 2016              |
| 11      | CNB - Adenoid cystic carcinoma        | 1     | Triple negative      | IPO-Porto   | 2017              |
| 12      | CNB - Adenoid cystic carcinoma        | NA    | Triple negative      | External    | 2017              |
| 13      | CNB - Atypical sclerosing lesion      | NA    | NA                   | External    | 2018              |

Institution, Institution where the biopsy was performed; FNA, Fine Needle Aspiration; CNB, Core Needle Biopsy; DCIS, Ductal Carcinoma In Situ; NA, Not available / Not applicable; HR, Hormonal Receptors; IPO-Porto, Instituto Português de Oncologia do Porto Francisco Gentil
Table 3: Surgical treatment and tumor characteristics.

| Patient | Surgery               | Tumor size (cm) | Grade | Synchronous disease | IHC                  | Re-excision | Final margins (cm) | TNM   |
|---------|-----------------------|-----------------|-------|---------------------|----------------------|-------------|-------------------|-------|
| 1       | Lumpectomy            | 1.7             | 1     | No                  | Triple negative      | MRM         | >1                | pT1N0M0 |
| 2       | MRM                   | 7.5             | 3     | No                  | Triple negative      | No          | >1                | pT4N2M0 |
| 3       | MRM                   | 1.8             | 2     | No                  | Positive ER (1-10%)  | No          | >1                | pT1N0M0 |
| 4       | Lumpectomy            | 1.6             | 1     | No                  | Positive ER (1-10%)  | No          | 0.3               | pT1N0M0 |
| 5       | Lumpectomy            | NA              | 1     | No                  | Negative HR          | Yes         | NA                | pT1N0M0 |
| 6       | Lumpectomy + SLNB     | 1.4             | 2     | No                  | Positive ER (10-20%) | No          | 0.1               | pT1N0M0 |
| 7       | Lumpectomy + SLNB     | 2.2             | 1     | Carcinoma in situ   | Triple negative      | No          | 0.1               | pT2N0M0 |
| 8       | Total mastectomy + SLNB | 1.9           | 1     | No                  | Triple negative      | No          | >1                | pT1N0M0 |
| 9       | Lumpectomy + SLNB     | 2.5             | 1     | Carcinoma in situ   | Positive ER (1-10%)  | Yes         | 0.3               | pT2N0M0 |
| 10      | Lumpectomy + SLNB     | 1.6             | 1     | No                  | Triple negative      | No          | 0.1               | pT1N0M0 |
| 11      | Total mastectomy + SLNB | 5.8           | 1     | No                  | Triple negative      | No          | >1                | pT3N0M0 |
| 12      | Lumpectomy + SLNB     | 3               | 1     | No                  | Triple negative      | No          | 0.2               | pT2N0M0 |
| 13      | Lumpectomy            | 2.3             | 2     | No                  | Triple negative      | No          | 0.1               | pT2N0M0 |

IHC, Immunohistochemistry; NA, Not available; MRM, Modified Radical Mastectomy; SLNB, sentinel lymph node biopsy; HR, Hormonal Receptors; ER, Estrogen Receptor; PR, Progesterone Receptor

Regarding treatment, surgical therapy was the first approach in all cases, with nine patients undergoing conservative surgery (69.2%) (Table 3). Mastectomy was chosen in case of unfavorable breast/tumor ratio or in the presence of comorbidities that precluded adjuvant therapy. Modified Radical Mastectomy
(MRM) was performed in confirmed cases of carcinoma before the implementation of sentinel lymph node biopsy at our institution. Since this technique was available, seven patients underwent this procedure, none revealing axillary metastasis. However, one of the cases of MRM revealed 6 metastatic lymph nodes out of 15 isolated ones. As for tumor dimension, the mean was 2.05cm (1.4–7.5cm). Nine cases had a triple negative phenotype or were HR negative (absence of expression of ER and PR), three cases were ER positive/PR negative and one was HR positive (ER positive/PR positive). Regarding tumor grade, nine were grade 1, three were grade 2 and one was grade 3. After the first surgical approach, two patients underwent re-excision and one an MRM. Free surgical margins were obtained in all cases: margins of 0.1cm were accepted in four patients, 0.2 or 0.3cm in three patients and greater than 1cm in the remaining. In this series, there were seven patients with stage I breast cancer (53.8%), five with stage II (38.5%) and one with stage III (7.7%).

Regarding adjuvant therapy, eight patients received radiotherapy, two were proposed for chemotherapy and one received hormone therapy, due to slightly higher ER expression levels. One of the patients proposed for adjuvant chemotherapy completed only one cycle due to febrile neutropenia and the other patient showed stage III ACCB (pT4N2M0) who was later considered unfit due to poor performance status.

With a median follow-up of 123 months (16–407), one case of local recurrence and two cases of distant metastases without local recurrence were identified in the patients with the bigger tumors of our sample, one of whom died of the disease (mortality rate of 7.7%) (Table 4). Regarding the case of local recurrence, it was detected at 186 months of follow-up and consisted of a triple negative multicentric ACCB (pT1N0, grade 1). This recurrence was treated with completion mastectomy and SLNB followed by adjuvant radiotherapy, due to surgical margins of 0.1cm. Currently, the patient is alive with no evidence of the disease. Concerning the first case of metastasis (a grade 3, stage III ACCB at diagnosis), it was detected at 4 months of follow-up in the form of bone metastases. The patient was proposed supportive treatment and died of the disease at 16 months of follow-up. The second case of metastasis (initially a grade 1, stage II ACCB) was diagnosed at 25 months of follow-up as bone and lung metastases. This was managed with antalgic radiotherapy, vertebroplasty of L5 and palliative chemotherapy, with good tolerance and stable disease after an initial partial response under AC (Doxorubicin and Cyclophosphamide, suspended due to toxicity), followed by capecitabine and currently lenvatinib after pulmonary progression.

Table 4. Adjuvant therapy and outcomes

| Patient | Adjuvant RT | Adjuvant CH | Adjuvant HT | Local recurrence | Distant metastasis | Survival data | Follow-up (months) |
|---------|-------------|-------------|-------------|------------------|-------------------|---------------|-------------------|
| 1       | No          | No          | No          | No               | No                | NED           | 402               |
| 2       | Yes         | No*         | No          | No               | Yes (bone metastasis) | DOD           | 16                |
| 3       | No          | No          | No          | No               | No                | DOC           | 242               |
| 4       | Yes         | No          | No          | No               | NED               | NED           | 212               |
| 5       | No          | No          | No          | No               | Yes (multicentric ACCB pT1N0) | NED           | 210               |
| 6       | Yes         | No          | Yes         | No               | No                | NED           | 199               |
| 7       | Yes         | Yes (1 cicle) | No          | No               | No                | DOC           | 141               |
| 8       | No          | No          | No          | No               | No                | NED           | 123               |
| 9       | Yes         | No          | No          | No               | No                | NED           | 63                |
| 10      | Yes         | No          | No          | No               | No                | NED           | 47                |
| 11      | No          | No          | No          | No               | Yes (bone and lung metastases) | AWD           | 48                |
| 12      | Yes         | No          | No          | No               | No                | NED           | 39                |
| 13      | Yes         | No          | No          | No               | No                | NED           | 31                |

RT, Radiotherapy; CH, Chemootherapy; HT, Hormone therapy; ACCB, Adenoid Cystic Carcinoma; NED, No evidence of disease; DOD, Dead of disease; DOC, Dead of other cause; AWD, Alive with disease; *Due to poor performance status.
DISCUSSION
The results obtained in our series are in line with those described in the literature. ACCB is a rare tumor (13 diagnosed patients in 33 years in our dedicated Oncological Center) with low malignant potential, rare locoregional recurrence or distant metastases, as opposed to other triple-negative breast cancers or the histologically similar and more aggressive adenoid cystic carcinoma of the salivary glands.1,19

ACCB was mainly found in postmenopausal women with a mean age of 68 years old which was slightly superior to the range of 50 to 60 years described in the literature. Patients presented mainly with a breast nodule, but it was mostly in the upper quadrants as opposed to a retroareolar location.1 In our series, there were 4 ER positive tumors (low expression, mostly 1-10%) and 1 PR positive tumor (low expression, 1-10%). Positivity for ER and PR has also been described in the literature in up to 46% and 36% of cases, respectively.3,19,25,26 Further analysis found no statistically significant differences in the clinical and histological features of ER/PR positive ACCB when compared to triple negative tumors, suggesting that the positive hormonal receptor status may not affect the prognosis.3 However, these results from Zhang et al. should be viewed with caution, as it was a single-center retrospective study of 14 patients, 8 being HR negative and only the remaining 6 being positive. In our study, none of the HR positive patients had locoregional recurrence or distant metastases. Similarly, at 31 and 212 months of follow-up, our three patients with grade 2 ACCB did not have a worse prognosis as it should have been expected, with two of the three cases of recurrence or metastases affecting grade 1 ACCB patients.

Two of the patients presented with a synchronous in situ carcinoma. The synchronous occurrence of an in situ or invasive carcinoma of another subtype has been described, and in these cases the prognosis is determined by that of the in situ or invasive carcinoma.21

Regarding the therapeutical regimen and after the required re-interventions, 8 patients were treated with conservative surgery and 7 of those with adjuvant radiotherapy. The patient submitted to a lumpectomy followed by re-excision without adjuvant radiotherapy was our only case of local recurrence, with our recurrence rate of 7.7% being consistent with that described in the literature (3-18%).2 However, we should not forget the evidence that adjuvant radiotherapy can decrease local recurrence.16,17

Concerning SNLB, some studies support its omission, given the low rate of positive nodes at diagnosis (about 5%),19 and after progression.24,25 Our results were similar with only one patient with axillary involvement at diagnosis (7.7%), also corresponding to one of the cases of distant metastasis. However, this was a grade 3 ACCB. The remaining case of distant metastatic disease was node negative at diagnosis. As previously stated, available evidence has reported the absence of nodal metastasis in tumors smaller than 1.4 – 2cm,6,21 but, despite our only case of nodal involvement happened in a 7.5cm tumor, we found no axillary metastasis in 11 patients that had tumors with a diameter of 1.4cm or greater, with 4 of them being greater than 2cm.

CONCLUSION
Considering ACCB’s favorable prognosis, establishing an accurate preoperative diagnosis is central to develop an appropriate treatment planning. Based on the literature and our findings in a dedicated Oncological Center, conservative surgery with free margins and adjuvant radiotherapy are the recommended treatments for ACCB. SLNB’s role is yet to be defined, but it seems reasonable to be omitted in grade 1 ACCB. This paper provided additional information on the best treatment of a rare tumor, aimed at preventing futile interventions such as the SLNB that could bear additional morbidity to the patient.

ACKNOWLEDGEMENTS
None.

CONFLICT OF INTEREST
None to declare.

REFERENCES
1. Lannaz S Ol, Bensouda Y, Mrabti H, Errihani H. A Rare Case of Adenoid Cystic Carcinoma of the Breast: Discussion and Review of the Literature Case Rep Clin Med. 2014;3(7):433-6. doi: 10.4236/crcm.2014.37096.
2. Treitl D RP, Rizer M, Hussein SE, Paramo JC, Mesko TW. Adenoid cystic carcinoma of the breast, 20 years of experience in a single center with review of literature. Breast Cancer. 2018 Jan;25(1):28-33. doi: 10.1007/s12282-017-0780-1.
3. Zhang W FY, Zhang Z, Wang J. Management of Adenoid Cystic Carcinoma of the Breast: A Single-Institution Study. Front Oncol. 2021;11: 621012. doi: 10.3389/fonc.2021.621012.
4. Wetterskog D L-GM, Lambros MB, A’Hern R, Geyer FC, Milanese F, et al. Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. J Pathol. 2012 Jan;226(1):84-96. doi: 10.1002/path.2974.
5. Naidoo K PS. Immunohistochemistry for Triple-Negative Breast Cancer. Methods Mol Biol. 2016;1406:39-51. doi: 10.1007/978-1-4939-3444-7_3.

6. Thompson K GI, Salzstein SL, Sadler GR, Blair SL. Adenoid cystic breast carcinoma: is axillary staging necessary in all cases? Results from the California Cancer Registry. Breast J. 2011 Sep-Oct;17(5):485-9. doi: 10.1111/j.1524-4747.2011.01117.x.

7. Veeratterapillay R VS, Ward E, Khout H, Fasih T. Adenoid cystic carcinoma of the breast: case report and review of literature. Ann R Coll Surg Engl. 2012 May;94(4):e137-8. doi: 10.1308/003588412X13171221499829.

8. Nozoe TE NE, Ohga T, Ezaki T, Sueishi K. A case of adenoid cystic carcinoma of the breast. J Med Invest. 2018;65(3.4):289-91. doi: 10.2152/jmi.65.289.

9. Cambruzzi E PK, Zettler CG, Zettler EW. Adenoid cystic carcinoma of the breast: a case report of a rare neoplasm. Rev AMRIGS. 2012 Apr-Jun;56 (2):161-163. Available at: https://pesquisa.bvsalud.org/portal/resource/pt/biblio.997892.

10. Tummidi S PS, Joshi D, Tandon A, Mohan A, Saxena P, et al. Adenoid Cystic Breast carcinoma: a Rare Entity. Indian J Surg Oncol. 2020 Sep;11(Suppl 2):226-231. doi: 10.1007/s13193-020-01106-0.

11. Gillie BK, Asarian A, Xiao P. Adenoid cystic carcinoma of the breast with distant metastasis to the liver and spleen: a case report. J Surg Case Rep. 2020 Nov;2020(11): rjaa483. doi: 10.1093/jscr/rjaa483.

12. Kander ER, Dhamme S, Solaris M, Jain S. Adenoid Cystic Carcinoma of the Breast from a Single-Center Cohort. Cancer Treat Com. 2015;4:182–7. doi: 10.1016/j.ctrc.2015.10.002.

13. Solek JM BM, Kalwas M, Jesionek-Kupnicka D, Romanška HM. Adenoid cystic carcinoma of the breast – an uncommon malignancy with unpredictable clinical behaviour. A case series of six patients. Contemp Oncol (Pozn). 2020;24(4): 263–265. doi: 10.5114/cr.2020.99025.

14. Ro JY SE, Gallagher HS. Adenoid cystic carcinoma of the breast. Hum Pathol. 1987 Dec;18(12):1276-81. doi: 10.1016/0046-8177(87)80413-6.

15. Board WCoTE. Breast Tumours. WHO Classification of Tumours. 2019; 5th ed., vol. 2, Lyon, France: International Agency for Research on Cancer. doi: https://dipot.ulb.ac.be/dspace/bitstream/2013/303138/3/Tan_et_al-2020-Histopathology.pdf.

16. Coates JM MS, Bold RJ, Chen SL. Adjuvant radiation therapy is associated with improved survival for adenoid cystic carcinoma of the breast. J Surg Oncol. 2010 Sep 15;102(4):342-7. doi: 10.1002/jso.21638.

17. Khanfir K KA, Villette S, Belkacemi Y, Vautravers C, Nguyen T, et al. Management of adenoid cystic carcinoma of the breast: a Rare Cancer Network study. Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):2118-24. doi: 10.1016/j.ijrobp.2010.12.008.

18. Senkus E KS, Ohno S, Penault-Llorca S, Poortmans P, Rutgers E, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26 Suppl 5:v8-30. doi: 10.1093/annonc/mdv298.

19. Kulkarni N PC, Greif JM, Klinberg VS, Bailey L, Korourian S, et al. Rare breast cancer: 933 adenoid cystic carcinomas from the National Cancer Data Base. Ann Surg Oncol. 2013 Jul; 20(7):2236-41. doi: 10.1245/s10434-013-2911-z.

20. Cannyilmaz E, UG, Menuş Y, Bahat Z, Yildiz K, Yoney A. Adenoid cystic carcinoma of the breast: A case report and literature review. Oncol Lett. 2014 May;7(5):1599-601. doi: 10.3892/ol.2014.1945.

21. Ghabach B AW, Curtis RE, Huycke MM, Lavigne JA, Dores GM. Adenoid cystic carcinoma of the breast in the United States (1977 to 2006): a population-based cohort study. Breast Cancer Res. 2010;12(4):R54. doi: 10.1186/bcr2613.

22. Mhamdi HA KH, Jungels C, Afifmos P, Belbaraka R, Piccart-Gebhart M. Adenoid cystic carcinoma of the breast - an aggressive presentation with pulmonary, kidney, and brain metastases: a case report. J Med Case Rep. 2017 Oct 29;11(1):303. doi: 10.1186/s13256-017-1459-0.

23. Kim M LD, Im J, Suh KJ, Keam B, Moon HG, et al. Adenoid cystic carcinoma of the breast: a case series of six patients and literature review. Cancer Res Treat. 2014 Jan;46(1):93-7. doi: 10.4143%2Fcrt.2014.46.1.93.

24. Welsh JL KM, Hoskin TL, Glazebrook KN, Boughhey JC, Shah SS, et al. Is axillary surgery beneficial for patients with adenoid cystic carcinoma of the breast? J Surg Oncol. 2017 Nov;116(6):690-695. doi: 10.1002/jso.24702.

25. Cadoor KA MO, O’Shea AM, Power CP, Hennessy BT. Management of unusual histological types of breast cancer. Oncologist. 2012;17(9):1135-45. doi: 10.1634%2Ffheoncologist.2012-0134.

26. Mastropasqua MG ME, Pruneri G, Orvieto E, Mazzarol G, Vento AR, et al. Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast. Mod Pathol. 2005 Oct;18(10):1277-82. doi: 10.1038/modpathol.3800423.